Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,363 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,404)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07472322 | ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 | not yet recruiting | Phase 1 / Phase 2 | 31 | University of Wisconsin, MadisonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 |
| clinicaltrials |
| NCT07707895 | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers | not yet recruiting | Phase 1 / Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | not yet recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07846358 | This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.(GFH276X1203) | not yet recruiting | Phase 1 / Phase 2 | 84 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT07698106 | Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC | not yet recruiting | Phase 1 / Phase 2 | 60 | University Health Network, TorontoOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07663630 | A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss | not yet recruiting | Phase 1 | 80 | PfizerINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT07842965 | CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial | not yet recruiting | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07217496 | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer | not yet recruiting | Phase 1 | 18 | ImmunityBio, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07800507 | Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | Yunnan Cancer HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07835737 | Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 78 | West China HospitalOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT05745740 | A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | not yet recruiting | Phase 1 / Phase 2 | 26 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07828236 | PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA | not yet recruiting | Phase 1 | 18 | Loki Therapeutics, Inc.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828249 | Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma(PRadR2) | not yet recruiting | Phase 1 | 26 | Centre Leon BerardOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07829185 | Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer(FALCON) | not yet recruiting | Phase 1 | 30 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07824960 | Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma(Panc 004) | not yet recruiting | Phase 1 / Phase 2 | 31 | University of VirginiaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07540832 | A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC | not yet recruiting | Phase 1 / Phase 2 | 80 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07818486 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | not yet recruiting | Phase 1 | 8 | Yong HeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors | not yet recruiting | Phase 1 | 74 | TwoStep Therapeutics, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07806500 | Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 | 18 | Beijing Anjianxi Bio-Medical Technology Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | not yet recruiting | Phase 1 | 285 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 130 | AbbVieINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07300475 | Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients | not yet recruiting | Phase 1 | 30 | Washington University School of MedicineOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07803653 | IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer | not yet recruiting | Phase 1 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07363408 | Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer | not yet recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07791758 | A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 369 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07798921 | JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure | not yet recruiting | Phase 1 | 36 | Yonsei UniversityOTHER | 0 | Sep 2, 2026 | clinicaltrials |
| NCT07355231 | Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI(GuidedRT) | not yet recruiting | Phase 1 / Phase 2 | 10 | Xemed LLCINDUSTRY | 0 | Sep 1, 2026 | clinicaltrials |
| NCT07796997 | GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy | not yet recruiting | Phase 1 | 20 | University of Illinois at ChicagoOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07632235 | A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai 6th People's HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07793578 | Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 32 | VA Office of Research and DevelopmentFED | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07596212 | BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder | not yet recruiting | Phase 1 / Phase 2 | 100 | University of Illinois at ChicagoOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07175389 | JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07772882 | Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer | not yet recruiting | Phase 1 | 24 | Rebecca ArendOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07768306 | Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM | not yet recruiting | Phase 1 | 20 | Norroy Bioscience Co., LTDINDUSTRY | 0 | Aug 17, 2026 | clinicaltrials |
| NCT05038098 | Magnetic Sentinel Lymph Node Mapping in Gastric Cancer | not yet recruiting | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06743555 | Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study(SAVED LUNG) | not yet recruiting | Phase 1 | 14 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07700212 | A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma | not yet recruiting | Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07552558 | Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | not yet recruiting | Phase 1 / Phase 2 | 45 | Washington University School of MedicineOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06055231 | PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis | not yet recruiting | Phase 1 | 40 | Roswell Park Cancer InstituteOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.(DUNP19) | not yet recruiting | Phase 1 | 16 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 288 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07650266 | A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma | not yet recruiting | Phase 1 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT06941480 | A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate | not yet recruiting | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials